Articles tagged with Breast Cancer Cells
Researchers have found that Cdk4 expression is essential for Ras-induced cancer development, making it a potential target for therapy. Dr. Hiroaki Kiyokawa and colleagues showed that Cdk4-deficient cells can enter a protective state of senescence when exposed to oncogenes like Ras.
A recent study found that high levels of cyclin E are closely associated with aggressive breast cancer, making it a powerful predictive marker. The presence of low molecular weight forms of cyclin E also showed strong prognostic value, indicating a higher risk of recurrence and spread.
Researchers used precancerous breast cells from patients with Li-Fraumeni syndrome to test the effectiveness of chemopreventive agents in preventing cancer. Treatment with tamoxifen, a p53-rescue drug, and PPAR-ã agonist showed promise in stopping cancer development, suggesting new potential therapies for high-risk individuals.
Researchers discovered deguelin's ability to selectively block the growth of precancerous and cancerous human bronchial epithelial cells. The study suggests deguelin may inhibit Akt activation, a critical cell survival signal for tumor progression.
Researchers investigate potential link between low-level exposure to zeranol and breast cancer risk. The study explores the biological effects of zeranol, a synthetic non-steroidal agent used in cattle feed, on human breast tissue.
Researchers at Cold Spring Harbor Laboratory have discovered a new breast cancer gene called DBC2, which is associated with sporadic breast cancer. The study shows that the Dbc2 protein kills cancer cells or stops them from growing, making it a promising target for treatment.
Researchers found that patients with advanced prostate cancer treated with zoledronic acid experienced fewer bone complications and less pain compared to those who received a placebo. Additionally, tumors in patients treated with the HuMV833 antiangiogenic antibody showed marked differences in antibody uptake, distribution, and clearance.
The study tracked the movement of individual cancer cells in real-time using computer automation. The research revealed similarities between breast and skin cancer strains, including oscillation and burrowing into tissue.
The incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma declined sharply in the mid-1990s, mainly due to AIDS treatment improvements. However, non-AIDS-associated non-Hodgkin's lymphoma incidence has continued to rise.
A recent study by Duke University researchers found that the Ras gene activates different signaling pathways in human cells, but not in mouse cells, to cause cancer. The study suggests a new protein target for anti-cancer drugs and highlights the differences between human and mouse cancers.
A Cornell University biochemist has developed a strategy to make tumor cells more sensitive to retinoic acid, reducing required doses and enhancing its anticancer activity. By introducing CRABP-II, a naturally occurring protein, researchers can boost RA's ability to inhibit breast cancer cell proliferation.
A research team led by Dr. Rakesh Kumar has discovered a new form of a protein associated with aggressive forms of cancer, including breast cancer. MTA1s appears to intercept the key protein receptor responsible for communicating with estrogen inside cells.
Researchers discovered a compound that selectively inhibits the growth of breast cancer cells engineered to overexpress HER-2, a protein implicated in 20-30% of human breast cancers. The compound, F16, targets the mitochondria of cancer cells, causing them to swell and eventually rupture, leading to cell death.
Researchers at Stanford University found that briefly disrupting a single mutant gene can permanently alter the course of cancer. The study, led by Dean Felsher, used a gene called MYC to induce cancer cells to revert to normal bone cells after treatment was stopped.
Researchers at Dana-Farber Cancer Institute have identified six new breast cancer-susceptibility genes, expanding the current list of eight known genes. The discovery provides a promising lead for developing targeted treatments and genetic tests to gauge inherited breast cancer risk.
Anal cancer is under-recognized, but rates of 350 cases per million in HIV-negative men and double in HIV-positive men indicate a need for prevention. Stanford researcher Mark Welton proposes an approach using yearly pap smears to detect precancerous cells before they develop into cancer.
A study published in the Journal of the National Cancer Institute found that genetic testing using breast cells can accurately predict breast cancer risk. The Gail model, a computer-based predictor, was correlated with DNA deletions and precancerous changes in cells, suggesting an individualized approach to risk assessment.
The American Cancer Society has awarded a $768,000 grant to Dr. Gloria Borgstahl to study the molecular processes that cause breast cancer. She is conducting related experiments on the International Space Station to understand how good cells turn bad and develop new treatments for the disease.
A test to detect the RhoC protein has shown promising early results, detecting invasive cancers with high specificity and identifying tiny tumors that have already metastasized. The study aims to identify early-stage cancer that could be vulnerable to aggressive treatment, potentially leading to improved patient outcomes.
Researchers have identified the mechanism behind tamoxifen's side effects, which may lead to the development of safer alternative medications. The study found that tamoxifen and raloxifene work differently in various cell types, with potential implications for breast cancer treatment.
Researchers have made promising strides in combating breast cancer using novel enzyme inhibitors that target key enzymes involved in cell growth and division. These drugs, such as R115777, work by interrupting cellular signals that promote tumor growth, leading to partial responses and disease stabilization in advanced cancer patients.
Scientists at MGH discover herceptin has additional antitumor properties by targeting multiple factors that maintain tumor blood supply, slowing growth and prolonging survival in animal models.
Scientists have developed a test to identify breast abnormalities that are more likely to develop into breast cancer. The test analyzes biological signals in cells and can help doctors determine whether certain women should receive prophylactic anti-oestrogen treatment or more frequent screening.
Combining trastuzumab and ZD1839 has been shown to be more effective in inhibiting breast cancer cell growth than using either treatment alone. The findings suggest a potential new approach for treating multiple types of cancers, including those with HER2 and EGFR gene mutations.
Researchers found that certain cancer drugs induce features of cellular aging, which can help stop the growth of cancer cells. The study suggests that some cancer treatments may have an unexpected side effect: causing premature aging in tumor cells.
Researchers have identified a compound in myrrh that kills cancer cells in the laboratory, showing promise for breast and prostate cancer prevention and treatment. The compound, which inactivates a specific protein overproduced by cancer cells, is estimated to be 100 times less potent than conventional chemotherapy drugs.
A new non-invasive technique using modified breast pumps to collect breast fluid samples shows promise in predicting breast cancer risk. Women with normal cells in their fluid are 30% more likely to develop cancer, while those with abnormal cells are twice as likely.
Researchers at the University of Washington have discovered a potential non-toxic cancer treatment using a wormwood derivative. The compound, artemisinin, selectively targets breast cancer cells by exploiting their high iron concentrations.
Researchers have created nanoscale atomic generators that selectively destroy cancer cells without harming healthy tissue. The generators use radioactive actinium to produce potent alpha particles that kill cancer cells, offering a new hope for treating various types of cancer.
A new molecular nanogenerator has been developed to target and destroy cancer cells using actinium-225. The treatment showed promising results in cell culture and animal models, killing cancer cells at extremely low concentrations.
A new study suggests that estrogen found in soy products with high isoflavone content may stimulate human breast-cancer cells in mice. Researchers warn women with estrogen-dependent breast cancer or a predisposition to it to reduce their consumption of such soy products.
The Phase II trial treating women with early-stage breast cancer has shown significant cell kill without damage to the skin. The technology uses adaptively focused microwave radiation that selectively heats and kills cancer cells, potentially reducing or eliminating breast surgery.
Researchers have uncovered evidence suggesting that genetic changes leading to breast cancer occur first in epithelial cells of breast tissue. LOH analysis reveals frequent mutations in both epithelial and stromal cells, indicating a multi-step process.
A new protein called Fbw7 has been found to control cyclin E levels in cells, which is associated with cancer progression. The study suggests that the absence of Fbw7 in breast cancer-derived cell cultures may indicate a tumor suppressor gene, suggesting its potential role in preventing malignant change.
Researchers found a black tea polyphenol compound, TF-2, that kills virtually all cancer cells while leaving normal cells intact. The compound also suppresses a gene associated with colon cancer and may be the reason for the chemopreventive activity of black tea extracts.
Researchers discovered that introducing a tiny mutation in the telomerase enzyme can trigger a DNA damage response, inducing cell-cycle arrest or cell death in human cancer cells. This approach could lead to a new therapeutic strategy for cancer treatment.
New research reveals estrogen can regress tamoxifen-resistant breast tumors by increasing apoptosis. Low levels of estradiol also inhibit tumor growth in raloxifene-resistant breast cancer cells.
Breast cancer cells migrate toward hormone source, with researchers identifying a novel prolactin-mediated mechanism driving metastasis. The discovery provides new insights into disease progression and suggests potential directions for developing drugs to block breast cancer growth.
Researchers at Cedars-Sinai Medical Center have discovered that a combination of the diabetes drug Troglitazone and Accutane can permanently inhibit the growth of breast cancer cells and induce programmed cell death. The treatment has shown no adverse effects on healthy cells in laboratory studies and animal experiments.